Terray Therapeutics Launches with $60M to Deliver Premium Chemical Data at Unrivaled Scale, Unlocking the Potential of AI-Driven Small Molecule Drug Discovery
Summary
In todays emerging frontier of AI-led drug discovery, Terrays chemistry engine operates at an unrivaled scale, measuring billions of interactions daily and becoming increasingly precise with each cycle of design and experimentation. Terray brings together a highly skilled, world-class team with deep pharma expertise and experience in AI, synthetic chemistry, biology, automation, and nanotechnology with the bold vision to harness the power of their discovery engine and put transformative therapeutics at our fingertips. "We are excited by the Companys world-class team of scientists and machine learning experts and the broad therapeutic potential of the tNova platform to drive solutions to our greatest medical problems." "Leveraging more than a decade of research from its founders, Terray has constructed a chemistry platform that systematically integrates high-throughput experimentation and computation at an unprecedented scale," said Geoffrey W. Smith, Managing Partner of Digitalis Ventures. "This integration sets Terray apart by addressing a key industry pain point, generating clean and relatable data that enables AI-driven models to succeed in the highly complex space of chemical compounds," added Dusan Perovic, Partner at Two Sigma Ventures.